AbbVie presented late‑breaking Phase 2 data for its antibody‑drug conjugate Mirvetuximab Soravtansine‑gynx (ELAHERE®) at the Society of Gynecologic Oncology (SGO) Annual Meeting on Sunday, April 12, 2026.
The data come from the IMGN853‑0420 trial, a multicenter, open‑label study of 125 patients with folate‑receptor‑alpha (FRα)‑positive, recurrent platinum‑sensitive ovarian cancer (PSOC). The regimen combined Mirvetuximab Soravtansine‑gynx with carboplatin for six to eight cycles, followed by single‑agent Mirvetuximab Soravtansine‑gynx. In the FRα ≥ 50% subgroup, the objective response rate (ORR) was 62.7 %; 81 % of patients experienced no disease progression and continued on the ADC monotherapy, and the median duration of response (DoR) across the overall population was 11.2 months.
These results extend the drug’s therapeutic reach beyond its current approval for platinum‑resistant disease, addressing an unmet need for patients who relapse after initial platinum‑based chemotherapy. The high ORR and durable responses in a platinum‑sensitive setting suggest that Mirvetuximab Soravtansine‑gynx could become a new standard of care for FRα‑positive PSOC.
AbbVie’s oncology strategy focuses on expanding its antibody‑drug conjugate portfolio. The positive Phase 2 data support the company’s plan to pursue broader indications for Mirvetuximab Soravtansine‑gynx and may inform future regulatory submissions and commercialization plans.
The ADC market is a key area of competition, with several companies developing targeted therapies for solid tumors. AbbVie’s investment in ImmunoGen, the original developer of Elahere, underscores its commitment to advancing ADC technology and positions the company to capture a larger share of the ovarian cancer market.
Overall, the late‑breaking data could influence AbbVie’s future regulatory strategy, broaden its oncology portfolio, and provide a new therapeutic option for patients with limited choices in the platinum‑sensitive ovarian cancer setting.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.